This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute lymphoblastic leukemia (ALL)	Notch 1 (NOTCH1); microRNA-181a (miR-181a); miR-181b-1	Mouse and cell culture studies suggest inhibiting miR-181a and miR-181b-1 could help treat NOTCH1 pathway-driven T cell ALL. In mouse models of the disease, miR-181a and miR-181b-1 knockout led to inhibition of oncogenic signaling and increased median survival compared with normal expression of both. Next steps could include evaluating pharmacological inhibitors of miR-181a and miR-181b-1.	Patent and licensing status unavailable	Fragoso, R. <i>et al. PLoS Genet.</i> ; published online Aug. 9, 2012; doi:10.1371/journal.pgen.1002855 Contact: Chang-Zheng Chen, Stanford University School of Medicine, Stanford, Calif. e-mail: czchen@stanford.edu
<i>SciBX</i> 5(34); doi:10.1038/scibx.2012.891 Published online Aug. 30, 2012				